Literature DB >> 20033077

Testing the glutamate hypothesis of schizophrenia.

Joshua A Gordon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20033077     DOI： 10.1038/nn0110-2

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN： 1097-6256            Impact factor:   24.884


× No keyword cloud information.
  10 in total

Review 1.  GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder.

Authors:  F M Benes; S Berretta
Journal:  Neuropsychopharmacology       Date:  2001-07       Impact factor: 7.853

2.  Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia.

Authors:  John H Krystal; Amit Anand; Bita Moghaddam
Journal:  Arch Gen Psychiatry       Date:  2002-07

Review 3.  Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.

Authors:  David A Lewis; Bita Moghaddam
Journal:  Arch Neurol       Date:  2006-10

Review 4.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.

Authors:  John E Lisman; Joseph T Coyle; Robert W Green; Daniel C Javitt; Francine M Benes; Stephan Heckers; Anthony A Grace
Journal:  Trends Neurosci       Date:  2008-04-07       Impact factor: 13.837

5.  Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia.

Authors:  T B Halene; R S Ehrlichman; Y Liang; E P Christian; G J Jonak; T L Gur; J A Blendy; H C Dow; E S Brodkin; F Schneider; R C Gur; S J Siegel
Journal:  Genes Brain Behav       Date:  2009-05-08       Impact factor: 3.449

Review 6.  Glutamate and schizophrenia: beyond the dopamine hypothesis.

Authors:  Joseph T Coyle
Journal:  Cell Mol Neurobiol       Date:  2006-06-14       Impact factor: 5.046

7.  Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.

Authors:  James L Reilly; Margret S H Harris; Matcheri S Keshavan; John A Sweeney
Journal:  Arch Gen Psychiatry       Date:  2006-11

8.  Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function.

Authors:  Gary E Duncan; Sheryl S Moy; Antonio Perez; Dawn M Eddy; Wendy M Zinzow; Jeffrey A Lieberman; John N Snouwaert; Beverly H Koller
Journal:  Behav Brain Res       Date:  2004-08-31       Impact factor: 3.332

Review 9.  Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Authors:  Sofie A M K Houthoofd; Manuel Morrens; Bernard G C Sabbe
Journal:  Clin Ther       Date:  2008-09       Impact factor: 3.393

10.  Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes.

Authors:  Juan E Belforte; Veronika Zsiros; Elyse R Sklar; Zhihong Jiang; Gu Yu; Yuqing Li; Elizabeth M Quinlan; Kazu Nakazawa
Journal:  Nat Neurosci       Date:  2009-11-15       Impact factor: 24.884
  10 in total
  23 in total

1.  Mice Lacking the Serotonin Htr2B Receptor Gene Present an Antipsychotic-Sensitive Schizophrenic-Like Phenotype.

Authors:  Pothitos M Pitychoutis; Arnauld Belmer; Imane Moutkine; Joëlle Adrien; Luc Maroteaux
Journal:  Neuropsychopharmacology       Date:  2015-05-04       Impact factor: 7.853

2.  Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP.

Authors:  Mirjana Carli; Eleonora Calcagno; Ester Mainini; Jorn Arnt; Roberto W Invernizzi
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

3.  Tract-based magnetic resonance spectroscopy of the cingulum bundles at 7 T.

Authors:  René C W Mandl; Martijn P van den Heuvel; Dennis W J Klomp; Vincent O Boer; Jeroen C W Siero; Peter R Luijten; Hilleke E Hulshoff Pol
Journal:  Hum Brain Mapp       Date:  2011-06-14       Impact factor: 5.038

4.  Sustained versus transient brain responses in schizophrenia: the role of intrinsic neural activity.

Authors:  Lauren Ethridge; Stephan Moratti; Yuan Gao; Andreas Keil; Brett A Clementz
Journal:  Schizophr Res       Date:  2011-08-11       Impact factor: 4.939

5.  (1)H-MRS and MEGA-PRESS pulse sequence in the study of balance of inhibitory and excitatory neurotransmitters in the human brain of ultra-high risk of schizophrenia patients.

Authors:  P E Menschikov; N A Semenova; M V Ublinskiy; T A Akhadov; R A Keshishyan; I S Lebedeva; M A Omelchenko; V G Kaleda; S D Varfolomeev
Journal:  Dokl Biochem Biophys       Date:  2016-07-15       Impact factor: 0.788

6.  Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain.

Authors:  Nina Segnitz; Thomas Ferbert; Andrea Schmitt; Peter Gass; Peter J Gebicke-Haerter; Mathias Zink
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

7.  Altered expression of schizophrenia-related genes in mice lacking mGlu5 receptors.

Authors:  Alessia Luoni; Peter Gass; Paolo Brambilla; Mirella Ruggeri; Marco A Riva; Dragos Inta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-08-31       Impact factor: 5.270

8.  An animal model of schizophrenia based on chronic LSD administration: old idea, new results.

Authors:  Danuta Marona-Lewicka; Charles D Nichols; David E Nichols
Journal:  Neuropharmacology       Date:  2011-02-23       Impact factor: 5.250

Review 9.  Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.

Authors:  Bita Moghaddam; John H Krystal
Journal:  Schizophr Bull       Date:  2012-08-16       Impact factor: 9.306

Review 10.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.